Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer
Ahmad Zulkifli, Fiona H Tan, Zammam Areeb, Sarah F Stuart, Juliana Gomez, Lucia Paradiso, Rodney B Luwor
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | MDPI | Published : 2021
Cetuximab is a common treatment option for patients with wild-type K-Ras colorectal carcinoma. However, patients often display intrinsic resistance or acquire resistance to cetuximab following treatment. Here we generate two human CRC cells with acquired resistance to cetuximab that are derived from cetuximab-sensitive parental cell lines. These cetuximab-resistant cells display greater in vitro proliferation, colony formation and migration, and in vivo tumour growth compared with their parental counterparts. To evaluate potential alternative therapeutics to cetuximab-acquired-resistant cells, we tested the efficacy of 38 current FDA-approved agents against our cetuximab-acquired-resistant c..View full abstract
Awarded by Victorian Cancer Agency Mid-Career Research Fellowship
R.B.L. is a recipient of the Victorian Cancer Agency Mid-Career Research Fellowship (MCRF15017).